A sarcoma is a type of cancer that develops from certain tissues, such as bone or muscle. There are 2 main types of sarcoma: osteosarcoma, which develops from bone, and soft tissue sarcomas. Soft tissue sarcomas can develop from soft tissues such as fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. They can be found in any part of the body. Most of them develop in the arms or legs. They can also be found in the trunk, head and neck area, internal organs, and the area in back of the abdominal cavity (known as the retroperitoneum). Sarcomas are not common tumors, and most cancers are the type of tumors called carcinomas.
In a phase 2 single-institution study, UCLA Jonsson Comprehensive Cancer Center researchers found that dose-equivalent preoperative radiation therapy for extremity/trunk soft tissue sarcoma delivered in five days rather than over the conventional five weeks produced similar benefits and treatment side effects.
Scientists at St. Jude Children's Research Hospital have revealed how the tumor suppressor gene PTEN plays a more important role in pediatric rhabdomyosarcoma than was previously appreciated.
Because gastrointestinal stromal tumors (GIST) are sensitive to the targeted small molecule therapy imatinib, oncologists tend to treat all patients with metastatic GIST with this drug. However, because this rare type of cancer is caused by different genetic mutations, imatinib does not help all patients equally.
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.
Scientists at the Sloan Kettering Institute have found that increased activity of a normal metabolic enzyme can lead to cancer. The enzyme, SHMT2, is a driver of a large portion of B cell lymphomas and could be a potential drug target.
A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found that treating soft tissue sarcoma with radiation over a significantly shorter period of time is safe, and likely just as effective, as a much longer conventional course of treatment.
Cancer patients responded better to immunotherapy and had a better prognosis if their melanoma tumors contained specific clusters of B cells, according to new research from Lund University in Sweden.
Some melanomas, sarcomas and renal cell carcinomas, but not all, have been found to respond dramatically to new drugs called immune checkpoint blockers, which exploit the body’s known capability to mount an immune response against the foreign antigen-bearing tumor cells.
Soft tissue sarcoma cells stop a key metabolic process which allows them to multiply and spread, and so restarting that process could leave these cancers vulnerable to a variety of treatments.
A new study in JNCI Cancer Spectrum finds that dramatic increases in cancer survival in adolescents and young adults are undermined by continuing disparities by race, ethnicity, and socioeconomic status.
The relative risk of a recurrence of cancer is reduced by 60% in dogs whose tumors are completely removed, a new analysis by Oregon State University researchers has found.
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.
Researchers have pinpointed a protein that plays a key role in a type of rare cancer often leading to tumours around joints and tendons, according to new findings in eLife.
The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).
Scientists at the University of Sheffield have discovered what keeps the perfect balance of breaks and repairs in our DNA - something which could help improve the success of chemotherapy and combat neurodegeneration associated with aging.
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to destroy the main tumor as well as leftover microscopic cancer cells that may seed other tumors.
Sarcoma is a rare and deadly form of cancer occurring in the bones and connective tissue that affects individuals of all ages.
Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after diagnosis has declined over time.
The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects.